The three startups – MedRX App (Ghana), PreMedicus and VeriPAD (both US) – were selected from over 140 applications from 30 countries around the world.
MedRX App connects patients in need of different medication to the pharmacies closest to them which have the medication in stock; PreMedicus allows users diagnose themselves with an illness even before they visit a doctor while VeriPAD helps laboratories and patients immediately identify if a medicine is counterfeit or not.
The startups have now joined the three months accelerator program at Metta Nairobi, which is run by Nest, a global accelerator.
Among other things, the startups will receive an equity-free funding of € 50,000 as well as access to Merck’s global network of experts for ongoing coaching and mentoring.
“It is amazing that not only the quantity of applications but also the quality of applications has substantially increased from the first intake to the second intake of the Merck Accelerator Africa,” said Karina Fassbender, innovation facilitator at Merck.
She added, “Also, the diversity of backgrounds and origins has increased as well. That made it easier to find not only the right startups that match our programme, but also to find synergies within the current intake and with our Alumni startups.”
The program will end in a Demo Day where the startups will pitch to potential investors and partners. It will hold during the last week of November 2016.
Aside the funds and other benefits, one of the startups will be selected to visit Merck’s newly opened hub in Silicon Valley in January.
This is the second edition of the digital health accelerator. The first edition saw three startups selected. It took place from April to June this year.